Acute lymphoblastic leukemia in adult first manifested as severe aplastic anemia--role of molecular analysis in correct diagnosis.

Abstract:

:Aplastic anemia (AA) may sometimes precede the diagnosis of acute lymphoblastic leukemia (ALL) in children. Such presentation of ALL is externally rare in adults and until now only few such cases have been reported. We present a 40-year-old male with ALL common type, which developed 14 months after the diagnosis of severe AA, successfully treated with corticosteroids. ALL was treated with standard induction chemotherapy but remission has not been achieved. The patient died 6 weeks after the diagnosis of ALL because of central nervous system bleeding. The pattern of IgH gene rearrangement analyzed with PCR method in bone marrow from the period of AA diagnosis and in peripheral blood mononuclear cells from ALL diagnosis showed two different monoclonal IgH configurations as the results of biallelic monoclonal rearrangement of IgH genes. The observed bands in both specimens were identical and indicated that leukemic cells originated from B-cell progenitor were also present in the bone marrow when AA was diagnosed. We suggest that molecular analysis of monoclonality in patients with AA may be important for proper selection of the rare cases of ALL first presenting as marrow aplasia.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Robak T,Bartkowiak J,Urbańska-Rys H,Szmigielska-Kapłon A,Strzelecka B,Chojnowski K

doi

10.1080/10428190290021605

keywords:

subject

Has Abstract

pub_date

2002-05-01 00:00:00

pages

1147-52

issue

5

eissn

1042-8194

issn

1029-2403

journal_volume

43

pub_type

杂志文章
  • Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.

    abstract::In chronic lymphocytic leukemia (CLL), strategies to overcome drug resistance due to p53 dysfunction are highly needed. Platinum-based compounds such as cisplatinum (CDDP) are active in fludarabine-refractory CLL through a largely unknown mechanism. We analyzed the mechanism of action of CDDP in the context of p53 dys...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.996751

    authors: Tonino SH,Mulkens CE,van Laar J,Derks IA,Suo G,Croon-de Boer F,van Oers MH,Eldering E,Wang JY,Kater AP

    更新日期:2015-01-01 00:00:00

  • Newer approaches in treating chronic myelogenous leukemia.

    abstract::We evaluated the recovery of human hematopoietic progenitors in long-term bone marrow culture (LTBMC) initiated in tissue culture (TC) flasks to that in "Lifecell" bags, which are gas-permeable plastic bags in which feeder-layer cells cannot adhere. Cells were incubated in presence of IL-1 and IL-3. Our experiments re...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309047901

    authors: Gulati SC,Lemoli R,Van Poznak C

    更新日期:1993-01-01 00:00:00

  • Monocytic myeloid-derived suppressor cells in chronic lymphocytic leukemia patients: a single center experience.

    abstract::This study aimed to analyze the frequency of peripheral Mo-myeloid-derived suppressor cells (Mo-MDSCs) in newly diagnosed CLL patients and to correlate their level with other prognostic factors such as frequency of CD38 cells and ZAP-70 cells and with the clinical response and survival outcomes in these patients. Fift...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1728747

    authors: Zahran AM,Moeen SM,Thabet AF,Rayan A,Abdel-Rahim MH,Mohamed WMY,Hetta HF

    更新日期:2020-07-01 00:00:00

  • Non-Hodgkin's lymphoma followed by plasmacytoma, both arising in A thyroid gland with Hashimoto's disease.

    abstract::We describe here a rare case of malignant lymphoma followed by plasmacytoma in Hashimoto's thyroiditis. The patient developed malignant lymphoma (small, non-cleaved cell, and non Burkitt's type by Working Formulation classification), and remained in remission for 2 years after receiving combination chemotherapy, and t...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428199909169627

    authors: Hasegawa Y,Itoh T,Tamagawa Y,Komeno T,Kojima H,Ninomiya H,Yatabe Y,Mori N,Nagasawa T

    更新日期:1999-11-01 00:00:00

  • Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations.

    abstract::The aim of this study was to assess the immunogenic potential of irradiated lymphoma cells in vivo and determine whether immunogenicity can be enhanced by modulation of the host immune system. Syngeneic murine lymphoma models irradiated ex vivo were used as an orthotopic cellular vaccination prior to challenge with vi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.769219

    authors: Honeychurch J,Melis MH,Dovedi SJ,Mu L,Illidge TM

    更新日期:2013-09-01 00:00:00

  • Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL).

    abstract::Ibrutinib is a first-in-class small molecule inhibitor that has shown remarkable efficacy in the treatment of CLL. Current guidelines recommend lifelong administration at a fixed daily dose of 420 mg. Data from real-world studies indicate up to 17.5% of patients discontinue ibrutinib due to toxicity. Hypothetically, j...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1554862

    authors: Akhtar OS,Attwood K,Lund I,Hare R,Hernandez-Ilizaliturri FJ,Torka P

    更新日期:2019-07-01 00:00:00

  • Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.

    abstract::Ponatinib is a pan-tyrosine kinase inhibitor (TKI) with efficacy in multirefractory CML patients who have failed other TKIs. Despite excellent response rates, resistance or intolerance may develop. We conducted a retrospective review of the outcome of patients with chronic (CP) and accelerated (AP) phase CML refractor...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1379076

    authors: Boddu P,Shah AR,Borthakur G,Verstovsek S,Garcia-Manero G,Daver N,Kadia T,Ravandi F,Jain N,Alhuraiji A,Burger J,Kornblau S,Pierce S,Dellasala S,Jabbour E,Kantarjian H,Cortes J

    更新日期:2018-06-01 00:00:00

  • Historical aspects and milestones in the development of effective treatment for hairy cell leukemia.

    abstract::Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder, but is gratifying to treat for both physicians and patients. During the 50 years since its initial description as a clinical entity, hematologists have been fascinated by the bizarre appearance of the malignant cell with its hair-like projections...

    journal_title:Leukemia & lymphoma

    pub_type: 历史文章,杂志文章,评审

    doi:10.3109/10428190903219667

    authors: Tallman MS,Polliack A

    更新日期:2009-10-01 00:00:00

  • Invasive fungal sinusitis: an effective combined treatment in five haematological patients.

    abstract::Invasive fungal rhinosinusitis (IFR) is a life-threatening infection. Its onset is subtle and a late diagnosis leads to severe complications. Death may occur within a few weeks notwithstanding treatment. We describe a comprehensive pre- and post-operative approach to care for haematological patients with IFR. Five hae...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701457923

    authors: Vener C,Carrabba M,Fracchiolla NS,Costa A,Fabio G,Hu C,Sina C,Guastella C,Pignataro L,Deliliers GL

    更新日期:2007-08-01 00:00:00

  • Multiple myeloma presenting clinically as lymphoma.

    abstract::Multiple myeloma typically presents with monoclonal proteinemia, marrow plasmacytosis, anemia, bony involvement, hypercalcemia and renal insufficiency. Less frequent presentations include hepatic and splenic enlargement (5% of cases), lymphadenopathy (4%) and biclonal gammopathy (1%). Chemotherapy may produce remissio...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709058347

    authors: Daeninck PJ,Williams GJ,Rubinger M,Johnston JB

    更新日期:1997-12-01 00:00:00

  • A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia.

    abstract::CXCR4 directs chronic lymphocytic leukemia (CLL) trafficking within protective tissue niches, and targeting CXCR4 with plerixafor may enhance drug sensitivity. We performed a phase 1 dose escalation study of plerixafor (NCT00694590) with rituximab in 24 patients with relapsed/refractory CLL. Patients received rituxima...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.1080/10428194.2019.1643463

    authors: Andritsos LA,Byrd JC,Cheverton P,Wu J,Sivina M,Kipps TJ,Burger JA

    更新日期:2019-12-01 00:00:00

  • Familial erythroleukemia: a distinct clinical and genetic type of familial leukemias.

    abstract::A family with erythroleukemia is presented, in which father and son were diagnosed at the same age, but 20 years apart, with almost identical clinical and morphological features of the disease. No environmental factors were identified. The karyotypic abnormalities of the bone marrow blasts in the son demonstrated 2 ma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809057551

    authors: Novik Y,Marino P,Makower DF,Wiernik PH

    更新日期:1998-07-01 00:00:00

  • Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.

    abstract::One hundred and ninety-six untreated de novo acute myeloid leukemia (AML) patients were treated with homoharringtonine + cytosine arabinoside (HA) based induction therapy composed of three chemotherapeutic drugs (HAD/M, D-daunorubicin-DNR, M-mitozantrone-MTZ) used in our hospital for the past 12 years. The patient pop...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701836852

    authors: Mi Y,Xue Y,Yu W,Liu S,Zhao Y,Meng Q,Bian S,Wang J

    更新日期:2008-03-01 00:00:00

  • Vincristine degradation by serum from leukemic patients: role of myeloperoxidase.

    abstract::Myeloperoxidase (MPO) has been shown to catalyze the in vitro degradation of vincristine (VCR). Given that MPO is a lysosomal enzyme that can be released into the circulation by both normal activated and leukemic myeloid cells, we investigated the possibility that sera from patients with acute myeloblastic leukemia (A...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609052426

    authors: Schlaifer D,Duchayne E,Demur C,Alvinerie P,Muller C,Attal M,Cooper MR,Payen C,Monsarrat B,Myers CE,Pris J,Laurent G

    更新日期:1996-02-01 00:00:00

  • Rituximab therapy in monoclonal IgM-related neuropathies.

    abstract::Monoclonal IgM-related neuropathies constitute a heterogeneous group of disorders, which are generally poorly responsive to treatment. Rituximab, a chimeric monoclonal antibody against the CD20 molecule, has been used with success in patients with neuropathy and monoclonal IgM with anti-MAG or anti-GM1 ganglioside act...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/14786410500441664

    authors: Kilidireas C,Anagnostopoulos A,Karandreas N,Mouselimi L,Dimopoulos MA

    更新日期:2006-05-01 00:00:00

  • Clinical applicability of proposed algorithm for identifying individuals at risk for hereditary hematologic malignancies.

    abstract::Multiple genes have been identified to cause hereditary predispositions to hematologic malignancies, and characterized by an increased risk to develop myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and/or aplastic anemia (AA). Referral algorithms for patients who may be at higher risk have been propose...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1630618

    authors: Clifford M,Bannon S,Bednar EM,Czerwinski J,Davis J,Dunnington L,Shahrukh Hashmi S,DiNardo CD

    更新日期:2019-12-01 00:00:00

  • Early human herpes virus type 6 reactivation in umbilical cord blood allogeneic stem cell transplantation.

    abstract::Human herpes virus type 6 can reactivate in patients after allogeneic stem cell transplantation and has been associated with serious sequelae such as delayed engraftment and an increased risk of developing acute graft-versus-host disease (GVHD). This study investigated human herpes virus type 6 (HHV-6) reactivation wi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2016.1157873

    authors: Cirrone F,Ippoliti C,Wang H,Zhou XK,Gergis U,Mayer S,Shore T,van Besien K

    更新日期:2016-11-01 00:00:00

  • Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.

    abstract::Management of relapsed lymphoma depends upon the variables of chemosensitive disease and successful stem cell mobilization. The microtubule specific agents, paclitaxel and vinorelbine, have efficacy in relapsed lymphoma and can enhance stem cell mobilization. We performed a phase I dose-escalation study of cytarabine ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600774923

    authors: Lonial S,Arellano M,Hutcherson D,Langston A,Flowers C,Heffner LT,Winton E,Jo Lechowicz M,Waller EK

    更新日期:2006-10-01 00:00:00

  • CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement.

    abstract::Platelet/endothelial cell adhesion molecule 1 (PECAM-1, CD31) is an immunoglobulin superfamily member expressed on the surface of platelets, leukocytes and endothelial cells. The role of CD31 in biology of lymphomas has not yet been systemically studied. Expression of cell surface CD31 was analyzed by flow cytometry o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1849678

    authors: Vockova P,Molinsky J,Klanova M,Karban J,Spacek M,Havranek O,Kupcova K,Kazantsev D,Trneny M,Klener P

    更新日期:2020-11-25 00:00:00

  • The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.

    abstract::Abstract ATM gene alteration is a frequent event in pathogenesis of chronic lymphocytic leukemia (CLL) and occurs as monoallelic loss in the form of 11q23 deletion, with and without mutation in the remaining ATM allele. ATM is a principal DNA damage response gene and biallelic ATM alterations lead to ATM functional lo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2013.829919

    authors: Stankovic T,Skowronska A

    更新日期:2014-06-01 00:00:00

  • Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.

    abstract::Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications. However, approximately 20-25% of patients develop resistance or intolerance to HU and must be treated with second-line therapies. Resistan...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2014.893310

    authors: Sever M,Newberry KJ,Verstovsek S

    更新日期:2014-12-01 00:00:00

  • In vitro effect of rGM-CSF on proliferation and maturation of leukemic cells from patients with acute myelogenous leukemia.

    abstract::We investigated the effect of rGM-CSF on the proliferation/differentiation balance of the leukemic cells maintained in liquid cultures during 7 days, from 16 patients with acute myelogenous leukemia (AML). Cell proliferation was measured by tritiated thymidine (3HT) incorporation, and by the plating efficiency (PE) ob...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309054735

    authors: Faussat-Suberville AM,Marie JP,Delmer A,Cadiou M,Zittoun R

    更新日期:1993-09-01 00:00:00

  • Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data.

    abstract::There is little evidence about whether additional risk stratification for adult patients with acute lymphoblastic leukemia age 65 and older is warranted. Using the Surveillance, Epidemiology, and End Results data linked to Medicare claims, we examined the effects of age, comorbid conditions, and mobility limitations o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1555329

    authors: Danese MD,Katz A,Cetin K,Chia V,Gleeson ML,Kelsh M,Griffiths RI

    更新日期:2019-08-01 00:00:00

  • Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.

    abstract::Cutaneous T-cell lymphomas (CTCL) are a group of non-Hodgkin lymphomas that typically present in the skin but can progress to systemic involvement. The optimal treatment for patients who relapse from or are refractory to systemic chemotherapy remains unclear. Romidepsin is a potent, class-I selective histone deacetyla...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1361022

    authors: Duvic M,Bates SE,Piekarz R,Eisch R,Kim YH,Lerner A,Robak T,Samtsov A,Becker JC,McCulloch W,Waksman J,Whittaker S

    更新日期:2018-04-01 00:00:00

  • The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.

    abstract::Patients with multiple myeloma who are refractory or intolerant to both bortezomib and lenalidomide have a poor prognosis. Next-generation therapies carfilzomib and pomalidomide have shown promising activity in this dual refractory population. Here we describe the clinical characteristics and ascertain the effects of ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.803547

    authors: Wang TF,Ahluwalia R,Fiala MA,Trinkaus KM,Cox DP,Jaenicke M,Moliske CC,Carson KR,Wildes TM,Tomasson MH,Stockerl-Goldstein KE,Vij R

    更新日期:2014-02-01 00:00:00

  • Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas.

    abstract::Bone marrow angiogenesis is increased in non-Hodgkin lymphomas (NHL). Compounds affecting extracellular matrix (ECM) may modify angiogenesis. Here we investigated ECM regulators in 48 unselected NHL patients compared with 35 controls. Untreated patients had elevated (P < 0.05) serum matrix metalloproteinase (MMP) 9 an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190902889270

    authors: Negaard HF,Svennevig K,Kolset SO,Iversen N,Lothe IM,Østenstad B,Sandset PM,Iversen PO

    更新日期:2009-06-01 00:00:00

  • Serum soluble interleukin-2 receptor levels in hairy cell leukemia: correlation with clinical and hematological parameters and with alpha-interferon treatment.

    abstract::The soluble Interleukin-2 Receptor (sIL-2R) serum levels were assessed in 42 patients with Hairy-Cell Leukemia (HCL) at diagnosis and after alpha-Interferon therapy and correlated with spleen size, peripheral hematological values, hairy cell index (HCI) and clinical response. Serum sIL-2R levels were significantly inc...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199209053608

    authors: Lauria F,Rondelli D,Raspadori D,Zinzani PL,Benfenati D,Pileri S,Sabattini E,Tura S

    更新日期:1992-05-01 00:00:00

  • Mutation of the ATM gene is not involved in the pathogenesis of either follicle center lymphoma or its transformation to higher-grade lymphoma.

    abstract::Loss of function of the ataxia-telangiectasia mutated (ATM) gene, located on human chromosome 11q22-23, is the cause of ataxia-telangiectasia (A-T), which is associated with an extremely high risk for lymphoma. Abnormalities in 11q22-23, including deletions and mutations of the ATM gene, have been reported in T-cell p...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290021623

    authors: Lossos IS,Thorstenson YR,Wayne TL,Oefner PJ,Levy R,Chu G

    更新日期:2002-05-01 00:00:00

  • Chronic myeloid leukemia stem cells and developing therapies.

    abstract::Chronic myeloid leukemia therapy has remarkably improved with the use of frontline BCR-ABL kinase inhibitors such that newly diagnosed patients have minimal disease manifestations or progression. Effective control of disease may also set the stage for eventual 'cure' of this leukemia. However, the existence of Philade...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2010.546921

    authors: Donato NJ,Peterson LF

    更新日期:2011-02-01 00:00:00

  • Derivative chromosome 9 deletions in chronic myeloid leukemia are associated with loss of tumor suppressor genes.

    abstract::It has recently been postulated that the absence of a single tumor suppressor gene (TSG) allele can provide a selective advantage for an emerging tumor cell. We have characterized the precise extension of the deletion on der(9) in 20 chronic myeloid leukemia (CML) cases using FISH analysis with an appropriate set of B...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001623900

    authors: Specchia G,Albano F,Anelli L,Storlazzi CT,Zagaria A,Liso A,Pannunzio A,Pastore D,Mestice A,Greco G,Liso V,Rocchi M

    更新日期:2004-04-01 00:00:00